Vipergen is a biotechnology company based in Copenhagen, Denmark, specializing in innovative small-molecule drug discovery services. The company is a leader in the use of DNA-encoded library (DEL) technologies, which enable the simultaneous screening of billions of small molecules for potential drug candidates. Vipergen's unique platforms, such as the Cellular Binder Trap Enrichment® (cBTE) technology, stand out because they allow DEL screening directly inside living cells, offering a more physiologically relevant approach. This method eliminates the need for purified target proteins and expands the range of druggable targets, making drug discovery faster and more efficient.

Vipergen collaborates with top-tier pharmaceutical and biotechnology companies worldwide, using its proprietary technologies to accelerate the identification of novel compounds for a variety of therapeutic areas.